MaxCyte (MXCT) vs NRC Health (NRC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
NRC Health (NRC) has outperformed MaxCyte (MXCT) over the past year, gaining 68.0% versus a loss of 32.9%. Over five years, NRC leads with a -52.9% price change compared with -90.6% for MXCT. NRC Health is the larger company by market cap ($446.6 million vs $107.3 million), about 4.2 times the size.
NRC Health pays a dividend yielding 2.97%, while MaxCyte does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MXCT | NRC |
|---|---|---|
| Share price | $1.04 | $20.19 |
| Market cap | $107.33M | $446.59M |
| 1-day change | -4.59% | +0.55% |
| YTD return | -32.90% | +7.57% |
| 1-year return | -32.90% | +67.97% |
| 5-year return | -90.57% | -52.92% |
| P/E ratio (TTM) | — | 84.13 |
| Forward P/E | — | 19.23 |
| EPS (TTM) | $-0.34 | $0.24 |
| Dividend yield | 0.00% | 2.97% |
| Annual dividend | $0.00 | $0.60 |
| 52-week high | $1.87 | $23.68 |
| 52-week low | $0.643 | $11.01 |
| Distance from 52-week high | -44.24% | -14.74% |
| Average volume | 691.26K | 115.43K |
| Shares outstanding | 103.21M | 22.12M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRC Health is about 4.2 times larger than MaxCyte by market value ($446.59M vs $107.33M).
- NRC has outperformed MXCT by 100.9 percentage points over the past year.
- NRC Health offers a meaningfully higher dividend yield (2.97% vs 0.00%).
MXCT vs NRC FAQ
Which is bigger, MaxCyte or NRC Health?
NRC Health (NRC) is larger, with a market capitalization of $446.59M compared with $107.33M for MaxCyte (MXCT).
Which stock has performed better over the past year, MXCT or NRC?
NRC returned +67.97% over the past 12 months, compared with -32.90% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, MaxCyte or NRC Health?
NRC Health pays a dividend yielding 2.97%, while MaxCyte does not currently pay a regular dividend.
Are MaxCyte and NRC Health in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.